Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
A number of other equities analysts have also issued reports on SGMO. Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the company a “hold” rating in a research report on Thursday. BidaskClub lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price (down from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $17.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $9.67.
Sangamo Therapeutics (SGMO) opened at 9.50 on Friday. Sangamo Therapeutics has a 52 week low of $2.65 and a 52 week high of $10.50. The stock’s market capitalization is $683.42 million. The firm has a 50-day moving average of $9.05 and a 200 day moving average of $6.12.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 50.76% and a negative net margin of 380.44%. The company had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. During the same period in the prior year, the company posted ($0.38) EPS. Sangamo Therapeutics’s quarterly revenue was up 124.3% on a year-over-year basis. On average, analysts anticipate that Sangamo Therapeutics will post ($0.93) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2800905/sangamo-therapeutics-inc-nasdaqsgmo-stock-rating-upgraded-by-valuengine.html.
In other news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the sale, the vice president now directly owns 35,517 shares in the company, valued at approximately $355,170. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.10% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. Candriam Luxembourg S.C.A. increased its stake in shares of Sangamo Therapeutics by 35.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 70,000 shares during the period. Highbridge Capital Management LLC purchased a new stake in shares of Sangamo Therapeutics during the first quarter worth $496,000. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Sangamo Therapeutics during the first quarter worth $154,000. Wells Fargo & Company MN increased its stake in shares of Sangamo Therapeutics by 13.0% in the first quarter. Wells Fargo & Company MN now owns 295,770 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 34,128 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 780 shares during the period. Institutional investors and hedge funds own 58.25% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.